Jump to content

Dopamine agonist

From Wikipedia, the free encyclopedia
Not to be confused with dopamine antagonist.
Dopamine agonist
Drug class
Skeletal structure diagram of dopamine
The skeletal structure of dopamine
Class identifiers
UseParkinson's disease, hyperprolactinemia, restless legs syndrome
ATC codeN04BC
Biological targetDopamine receptors
External links
MeSHD010300
Legal status
In Wikidata

A dopamine agonist is a compound that activates dopamine receptors. There are two families of dopamine receptors, D1-like and D2-like. They are all G protein-coupled receptors. D1- and D5-receptors belong to the D1-like family and the D2-like family includes D2, D3 and D4 receptors.[1] Dopamine agonists are primarily used in the treatment of the motor symptoms of Parkinson's disease, and to a lesser extent, in hyperprolactinemia and restless legs syndrome.[2][3] They are also used off-label in the treatment of clinical depression. Impulse control disorders are associated with the use of dopamine agonists for whatever condition.[3]

Medical uses

[edit]
G protein-coupled receptors

Parkinson's disease

[edit]

Dopamine agonists are mainly used in the treatment of Parkinson's disease.[2]  The cause of Parkinson's is not fully known but genetic factors, for example specific genetic mutations, and environmental triggers have been linked to the disease.[4] In Parkinson's disease dopaminergic neurons that produce the neurotransmitter dopamine in the brain slowly break down and can eventually die. With decreasing levels of dopamine the brain can't function properly and causes abnormal brain activity, which ultimately leads to the symptoms of Parkinson's disease.[5]

dopamine

There are two fundamental ways of treating Parkinson's disease, either by replacing dopamine or mimicking its effect.[1]

Dopamine agonists act directly on the dopamine receptors and mimic dopamine's effect.[1] Dopamine agonists have two subclasses: ergoline and non-ergoline agonists. Both subclasses target dopamine D2-type receptors. Types of ergoline agonists are cabergoline and bromocriptine and examples of non-ergoline agonists are pramipexole, ropinirole and rotigotine. Ergoline agonists are much less used nowadays because of the risk of cartilage formation in heart valves.[6][7]

Treatment of depression in Parkinson's patients

[edit]

Depressive symptoms and disorders are common in patients with Parkinson's disease and can affect their quality of life.[8] Increased anxiety can accentuate the symptoms of Parkinson's and is therefore essential to treat. Instead of conventional antidepressant medication in treating depression, treatment with dopamine agonists has been suggested.[9] It is mainly thought that dopamine agonists help with treating depressive symptoms and disorders by alleviating motor complications, which is one of the main symptoms of Parkinson's disease.  Although preliminary evidence of clinical trials has shown interesting results, further research odds crucial to establish the anti-depressive effects of dopamine agonists in treating depressive symptoms and disorders in those with Parkinson's.[8][10]

Hyperprolactinemia

[edit]

Dopamine is a prolactin-inhibiting factor (PIFs) since it lowers the prolactin-releasing factors (PRFs) synthesis and secretion through D2-like receptors.[11] That is why dopamine agonists are the first-line treatment in hyperprolactinaemia.[12] Ergoline-derived agents, bromocriptine and cabergoline are mostly used in treatment. Research shows that these agents reduce the size of prolactinomas by suppressing the hypersecretion of prolactin resulting in normal gonadal function.[13]

Restless leg syndrome

[edit]

Numerous clinical trials have been performed to assess the use of dopamine agonists for the treatment of restless legs syndrome (RLS). RLS is identified by the strong urge to move and is a dopamine-dependent disorder. RLS symptoms decrease with the use of drugs that stimulate dopamine receptors and increase dopamine levels, such as dopamine agonists.[14]

Adverse effects

[edit]

Side effects

[edit]

Dopamine agonists are mainly used to treat Parkinson's disease, but also hyperprolactinemia and restless legs syndrome.[15] The side effects are predominantly collected from studies of Parkinson's disease, where dopamine agonists are commonly used as a first-line treatment with levodopa.[16]

Dopamine agonists are divided into two subgroups or drug classes, first-generation and newer agents. Ergoline derived agonists comprise the first generation; more widely used today are the non-ergoline derived agents. Ergoline derived agonists are generally less selective and tend to show interactions with receptors other than dopamine receptors, which can cause more side effects. Bromocriptine, cabergoline, pergolide and lisuride are examples of ergoline derived agonists. Non-ergoline agonists include pramipexole, ropinirole, rotigotine, piribedil and apomorphine.[1]

The most common adverse effects are constipation, nausea and headaches. Other serious side effects are hallucinations, peripheral edema, gastrointestinal ulcers, pulmonary fibrosis and psychosis.[1][16]

Dopamine agonists have been linked to cardiac problems, with side effects such as hypotension, myocardial infarction, congestive heart failure, cardiac fibrosis, pericardial effusion and tachycardia.[1] A high risk for valvular heart disease has been established in association with ergot-derived agonists especially in elderly patients with hypertension.[17]

In some studies, almost 30% of patients are reported to have suffered from somnolence and sleep attacks when using dopamine agonists. Daytime sleepiness, insomnia and other sleep disturbances are also frequently associated with the use of these drugs.[1][18][19]

Impulse control disorder, which manifests in behaviors such as gambling, hypersexuality, compulsive shopping or binge eating, can be another serious adverse effect of dopamine agonists.[15]

After long-term use of dopamine agonists a withdrawal syndrome may occur when discontinuing the drug or reducing the dose. The following side effects are possible: anxiety, panic attacks, dysphoria, depression, agitation, irritability, suicidal ideation, fatigue, orthostatic hypotension, nausea, vomiting, diaphoresis, generalised pain and drug cravings. For some individuals, these withdrawal symptoms are short-lived, and they make a full recovery. For others, a protracted withdrawal syndrome may occur with symptoms persisting for months or years.[20]

Interactions

[edit]

Dopamine agonists interact with a number of drugs but there is little evidence that they interact with other Parkinson's drugs. In most cases there is no reason not to co-administer Parkinson's drugs, but there have been indications that the concurrent use of dopamine agonists with L-DOPA can cause psychosis, and therefore in these cases it is recommended that either the dopamine agonist(s) be discontinued or the dose of L-DOPA reduced. Since ergot-dopamine agonist have antihypertensive qualities it is wise to monitor blood pressure when using dopamine agonists with antihypertensive drugs to ensure that the patient does not get hypotension. That includes the drug sildenafil which is commonly used to treat erectile dysfunction but also used for pulmonary hypertension.[21]

There is evidence that suggests that since ergot dopamine agonists are metabolized by CYP3A4 enzyme concentration rises with the use of CYP3A4 inhibitors. For example, in one study bromocriptine was given with a CYP3A4 inhibitor and the AUC (area under the curve) increased 268%. Ropinirole is a non-ergot derived dopamine agonist and concomitant use with a CYP1A2 inhibitor can result in a higher concentration of ropinirole. When discontinuing the CYP1A2 inhibitor, if using both drugs, there is a chance that a dose adjustment for ropinirole is needed. There is also evidence the dopamine agonists inhibit various CYP enzymes and therefore they may inhibit the metabolism of certain drugs.[16]

Pharmacokinetics

[edit]

Pharmacokinetics is the study of how a drug moves through the body, involving four main processes: absorption, distribution, metabolism, and excretion. Absorption refers to how the drug enters the bloodstream after administration. Distribution describes how the drug spreads throughout the body's tissues and organs. Metabolism involves the breakdown of the drug, typically in the liver. Finally, excretion is how the drug or its metabolites are eliminated from the body, often through urine or feces (Gibaldi & Perrier, 1982).[22]

Ergolines

[edit]

Bromocriptine

[edit]

Absorption of bromocriptine oral dose is approximately 28%; however, only 6% reaches the systemic circulation unchanged, due to a substantial first-pass effect. Bromocriptine reaches mean peak plasma levels after about 1–1.5 hours after a single oral dose. The drug has high protein binding, ranging from 90-96% bound to serum albumin. Bromocriptine is metabolized by CYP3A4 and excreted primarily in the feces via biliary secretion. Metabolites and parent drugs are mostly excreted via the liver, but also 6% via the kidney. It has a half-life of 2–8 hours.[1]

Pergolide

[edit]

Pergolide has a long half-life of about 27 hours and reaches a mean peak plasma level in about 2–3 hours after a single oral dose. The protein binding is 90% and the drug is mainly metabolized in the liver by CYP3A4 and CYP2D6. The major route of excretion is through the kidneys.[1][23]

Drug Maintenance Half-life Protein binding Peak plasma Metabolism Excretion
Bromocriptine

Oral, 2.5–40 mg/day

2–8 hours 90-96% 1-1,5 hours

Hepatic, via CYP3A4, 93% first-pass metabolism

Bile, 94-98%

Renal, 2-6%

Pergolide

Oral, 0.05 mg/day Usual response up to 0.1 mg per day

27 hours 90% 2–3 hours Extensively hepatic Renal, 50%

Fecal 50%

Non-ergolines

[edit]

Pramipexole

[edit]

Pramipexole reaches maximum plasma concentration 1–3 hours post-dose. It is about 15% bound to plasma proteins and the metabolism is minimal. Pramipexole has a long half-life, around 27 hours. The drug is mostly excreted in the urine, around 90%, but also in feces.[1]

Ropinirole

[edit]

Ropinirole is rapidly absorbed after a single oral dose, reaching plasma concentration in approximately 1–2 hours. The half-life is around 5–6 hours. Ropinirole is heavily metabolized by the liver and in vitro studies show that the enzyme involved in the metabolism of ropinirole is CYP1A2.[24]

Rotigotine

[edit]

Since rotigotine is a transdermal patch it provides continuous drug delivery over 24 hours.[25] It has a half-life of 3 hours and the protein binding is around 92% in vitro and 89.5% in vivo. Rotigotine is extensively and rapidly metabolized in the liver and by the CYP enzymes. The drug is mostly excreted in urine (71%), but also in feces (23%).[1]

Drug Maintenance Half-life Protein binding Peak plasma Metabolism Excretion
Pramipexole

Oral, 0.125 mg 3x/day (IR) Oral, 0.375 mg/day (ER)

8–12 hours 15% 1–3 hours Minimal < 10% Urine 90%

Fecal 2%

Ropinirole

Oral, 0.25 mg 3x/day (IR) Oral, 2 mg/day (ER)

5–6 hours 10-40% 1–2 hours Hepatic, via P450 CYP1A2 — can increase ↑ INR Renal > 88%
Rotigotine

Transdermal, 2 – 4 mg/day

3 hours

92%

24 hours Hepatic (CYP-mediated). Urine 71%

Fecal 23%

Mechanism of action

[edit]

The dopamine receptors are members of the G protein-coupled receptors superfamily with seven transmembrane domains. Dopamine receptors have five subtypes, D1 through D5, the subtypes can be divided into two subclasses due to their mechanism of action on adenylate cyclase enzyme, D1-like receptors (D1 and D5) and D2-like receptors (D2, D3 and D4). D1-like receptors are primarily coupled to Gαs/olf proteins and activates adenylate cyclase which increases intracellular levels of cAMP, they also activate the Gβγ complex and the N-type Ca2+ channel. D2-like receptors decrease intracellular levels of the second messenger cAMP by inhibiting adenylate cyclase.[26][27]

Bromocriptine

[edit]

Bromocriptine is an ergot derivative, semi-synthetic. Bromocriptine is a D2 receptor agonist and D1 receptor antagonist with a binding affinity to D2 receptors of anterior pituitary cells, exclusively on lactotrophs. Bromocriptine stimulates Na+, K+-ATPase activity and/or cytosolic Ca2+ elevation and therefore reduction of prolactin which leads to no production of cAMP.

Pramipexole

[edit]

Pramipexole is a highly active non-ergot D2-like receptor agonist with a higher binding affinity to D3 receptors rather than D2 or D4 receptors. The mechanism of action of pramipexole is mostly unknown, it is thought to be involved in the activation of dopamine receptors in the area of the brain where the striatum and the substantia nigra is located. This stimulation of dopamine receptors in the striatum may lead to the better movement performance.[28]

Structure–activity relationship

[edit]
Further information: Structure–activity relationship

When dealing with agonists it can be extremely complex to confirm relationships between structure and biological activity. Agonists generate responses from living tissues. Therefore, their activity depends both on their efficacy to activate receptors and their affinity to bind to receptors.[29]

Crossing the blood brain barrier

[edit]

Many molecules are unable to cross the blood–brain barrier (BBB). Molecules must be small, non-polar and lipophilic to cross over. Compounds without these qualities must have a specific transporter that can transport them over the BBB.[30] Dopamine cannot diffuse across the BBB because of the catechol group, it is too polar and therefore unable to enter the brain. The catechol group is a dihydroxy benzene ring.

The synthesis of dopamine consists of three stages. The synthesis process starts with an amino acid, called L-tyrosine. In the second stage L-DOPA (levodopa) is formed by adding a phenol group to the benzene ring of L-tyrosine. The formation of L-DOPA from L-tyrosine is catalyzed by the enzyme tyrosine hydroxylase. The third stage is the formation of dopamine by removing the carboxylic acid group from L-DOPA, catalysed by the enzyme dopa decarboxylase.[31]

Levodopa is also too polar to cross the blood brain barrier but it is an amino acid and has a specialized transporter called L-type amino acid transporter or LAT-1 that helps it diffuse through the barrier.[32]

Dopamine

[edit]

When dopamine interacts with ATP, which is a component of some dopamine receptors, it has a significant preference for a trans-conformation of the dopamine molecule. The dopamine-ATP complex is stabilised by hydrogen bonding between catechol hydroxyls and purine nitrogens and by electrostatic interactions between the protonated ammonium group of dopamine and a negative phosphate group. Two conformers of dopamine have been identified as alpha- and beta-conformers in which the catechol ring is coplanar with the plane of the ethylamine side chain. They are substantial in agonist-receptor interactions.[33]

Ergoline derivatives

[edit]

Central dopaminergic agonist properties of semisynthetic ergoline derivatives lergotrile, pergolide, bromocriptine and lisuride have been established. Some studies suggest that ergot alkaloids have the properties of mixed agonist-antagonist with regards to certain presynaptic and postsynaptic receptors. N-n-Propyl groups (chemical formula: –CH2CH2CH3) frequently enhance dopamine agonist effects in the ergoline derivatives.

Bromocriptine

The (+)-enantiomer displays notably diminished activity whereas the (-)-enantiomer possess potent dopamine agonist properties.[33]

Bromocriptine

[edit]

Bromocriptine has an ergot alkaloid structure. Ergot alkaloids are divided into 2 groups; amino acid ergot alkaloids and amine ergot alkaloids, bromocriptine is part of the former group.[34] It contains a bromine halogen on the ergot structure which increases the affinity for the D2-receptor but often reduces the efficacy. The similarity between the dopamine structure and the ergoline ring in bromocriptine is likely the cause for its action on the dopamine receptors.[35] It has shown to have equal affinity for D2- and D3-receptor and much lower affinity for D1-receptor.[36]

Apomorphine

Non-ergoline derivatives

[edit]

Non-ergoline dopamine receptor agonists have higher binding affinity to dopamine D3-receptors than dopamine D2-receptors. This binding affinity is related to D2 and D3 receptor homology, the homology between them has a high degree of sequence and is closest in their transmembrane domains, were they share around 75% of the amino acid.[37]

Rotigotine

Apomorphine

[edit]

Apomorphine has a catechol element and belongs to a class called β-phenylethylamines and its main components are similar to the dopamine structure. The effect that apomorphine has on the dopamine receptors can also be linked to the similarities between its structure and dopamine.[38] It is a chiral molecule and thus can be acquired in both the R and S form, the R form is the one that is used in therapy. When apomorphine interacts with the dopamine receptor, or the ATP on the receptor, the catechol and nitrogen are important to stabilize the structure with hydrogen bonding. The position of the hydroxyl groups is also important and monohydroxy derivatives have been found to be less potent than the dihydroxy groups. There are a number of stability concerns with apomorphine such as oxidation and racemization.[39]

Rotigotine

[edit]

Rotigotine is a phenolic amine and thus has poor oral bioavailability and fast clearance from the body. Therefore, it has been formulated as a transdermal patch, first and foremost to prevent first pass metabolism in the liver.[40]

Members

[edit]

Examples of dopamine agonists include:

Partial agonist

[edit]

Agonists of full/unknown efficacy

[edit]

Some, such as fenoldopam, are selective for dopamine receptor D1.[45]

[edit]

There are two classes of drugs that act as indirect agonists of dopamine receptors: dopamine reuptake inhibitors and dopamine releasing agents. These are not considered dopamine agonists, since they have no specific agonist activity at dopamine receptors, but they are nonetheless related. Indirect agonists are prescribed for a wider range of conditions than standard dopamine agonists.

The most commonly prescribed indirect agonists of dopamine receptors include:

Other examples include:

History

[edit]

Since the late 1960 Levodopa (L-DOPA) has been used to treat Parkinson's disease but there has always been a debate whether the treatment is worth the side effects.[47] Around 1970 clinicians started using the dopamine agonist apomorphine alongside L-DOPA to minimize the side effects caused by L-DOPA, the dopamine agonists bind to the dopamine receptor in the absence of dopamine. Apomorphine had limited use since it had considerable side effects and difficulty with administration. In 1974 bromocriptine was use widely after clinicians discovered its benefits in treating Parkinsons.[48] When using the two drug classes together there is a possibility to reduce the amount of L-DOPA by 20-30% and thus keeping the fluctuating motor responses to a minimum.[7] Dopamine agonists are often used in younger people as monotherapy and as initial therapy instead of L-DOPA.[7] Although it is important to know that there is a correlation between the two drugs, if l-DOPA doesn't work dopamine agonists are also ineffective.[1]

The early dopamine agonists, such as bromocriptine, were ergot derived and activated the D2-receptor.[7] They induced major side effects such as fibrosis of cardiac valves. It is considered that the reason they induced such side effects is that they activate many types of receptors.[1]

Due to the major adverse effects of ergot-derived dopamine agonists, they are generally not used in modern medicine and have mostly been abandoned in favor of non-ergot agonists such as pramipexole, ropinirole and rotigotine. They do not induce as serious side effects although common side effects are nausea, edema and hypotension. Patients have also shown impaired impulse control such as overspending, hypersexuality and gambling.[49]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k l m Borovac JA (March 2016). "Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology". The Yale Journal of Biology and Medicine. 89 (1): 37–47. PMC 4797835. PMID 27505015.
  2. ^ a b Silva MA, Mattern C, Häcker R, Tomaz C, Huston JP, Schwarting RK (December 1997). "Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment". Synapse. 27 (4): 294–302. doi:10.1002/(sici)1098-2396(199712)27:4<294::aid-syn3>3.3.co;2-z. PMID 9372552.
  3. ^ a b Spencer H, Anderton RS (2024). "Trait Impulsivity as a Feature of Parkinson's Disease Treatment and Progression". Parkinsons Dis. 2024: 8770997. doi:10.1155/2024/8770997. PMC 11102119. PMID 38766569.
  4. ^ Howes OD, McCutcheon R, Owen MJ, Murray RM (January 2017). "The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia". Biological Psychiatry. 81 (1): 9–20. doi:10.1016/j.biopsych.2016.07.014. PMC 5675052. PMID 27720198.
  5. ^ DeMaagd G, Philip A (August 2015). "Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis". P & T. 40 (8): 504–32. PMC 4517533. PMID 26236139.
  6. ^ Antonini, Angelo; Poewe, Werner (2007). "Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease". The Lancet Neurology. 6 (9). Elsevier BV: 826–829. doi:10.1016/s1474-4422(07)70218-1. ISSN 1474-4422. PMID 17706566. S2CID 39526238.
  7. ^ a b c d Brooks DJ (June 2000). "Dopamine agonists: their role in the treatment of Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry. 68 (6): 685–9. doi:10.1136/jnnp.68.6.685. PMC 1736955. PMID 10811688.
  8. ^ a b Barone P (March 2011). "Treatment of depressive symptoms in Parkinson's disease". European Journal of Neurology. 18 (Suppl 1): 11–5. doi:10.1111/j.1468-1331.2010.03325.x. PMID 21255198. S2CID 5827695.
  9. ^ Leentjens AF (February 2011). "The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review". Drugs. 71 (3): 273–86. doi:10.2165/11585380-000000000-00000. PMID 21319866. S2CID 38988462.
  10. ^ Trenkwalder, Claudia (2005), "Parkinsonism", Principles and Practice of Sleep Medicine, Elsevier, pp. 801–810, doi:10.1016/b0-72-160797-7/50074-4, ISBN 978-0-7216-0797-9, retrieved 2024-06-02
  11. ^ Mancini, Tatiana; Casanueva, Felipe F.; Giustina, Andrea (2008-03-01). "Hyperprolactinemia and Prolactinomas". Endocrinology and Metabolism Clinics of North America. Pituitary Disorders. 37 (1): 67–99. doi:10.1016/j.ecl.2007.10.013. ISSN 0889-8529. PMID 18226731.
  12. ^ Verhelst, Johan; Abs, Roger; Maiter, Dominique; van den Bruel, Annick; Vandeweghe, Mark; Velkeniers, Brigitte; Mockel, Jean; Lamberigts, Gerard; Petrossians, Patrick; Coremans, Peter; Mahler, Charles (1999-07-01). "Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients". The Journal of Clinical Endocrinology & Metabolism. 84 (7): 2518–2522. doi:10.1210/jcem.84.7.5810. ISSN 0021-972X. PMID 10404830.
  13. ^ Webster, Jonathan; Piscitelli, Gabriella; Polli, Anna; Ferrari, Carlo I.; Ismail, Ikram; Scanlon, Maurice F. (1994-10-06). "A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea". New England Journal of Medicine. 331 (14): 904–909. doi:10.1056/NEJM199410063311403. ISSN 0028-4793. PMID 7915824.
  14. ^ Zintzaras E, Kitsios GD, Papathanasiou AA, Konitsiotis S, Miligkos M, Rodopoulou P, Hadjigeorgiou GM (February 2010). "Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis". Clinical Therapeutics. 32 (2): 221–37. doi:10.1016/j.clinthera.2010.01.028. PMID 20206780.
  15. ^ a b Moore TJ, Glenmullen J, Mattison DR (December 2014). "Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs". JAMA Internal Medicine. 174 (12): 1930–3. doi:10.1001/jamainternmed.2014.5262. PMID 25329919.
  16. ^ a b c Kvernmo T, Härtter S, Burger E (August 2006). "A review of the receptor-binding and pharmacokinetic properties of dopamine agonists". Clinical Therapeutics. 28 (8): 1065–1078. doi:10.1016/j.clinthera.2006.08.004. PMID 16982285.
  17. ^ Peralta C, Wolf E, Alber H, Seppi K, Müller S, Bösch S, et al. (August 2006). "Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study". Movement Disorders. 21 (8): 1109–13. doi:10.1002/mds.20887. PMID 16622856. S2CID 26909111.
  18. ^ Wood LD (April 2010). "Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease". Drugs & Aging. 27 (4): 295–310. doi:10.2165/11318330-000000000-00000. PMID 20359261. S2CID 21096318.
  19. ^ Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD (July 2015). "Development of excessive daytime sleepiness in early Parkinson disease". Neurology. 85 (2): 162–8. doi:10.1212/WNL.0000000000001737. PMID 26085603. S2CID 17598980.
  20. ^ Nirenberg MJ (August 2013). "Dopamine agonist withdrawal syndrome: implications for patient care". Drugs & Aging. 30 (8): 587–92. doi:10.1007/s40266-013-0090-z. PMID 23686524. S2CID 207489653.
  21. ^ Jost WH, Brück C (October 2002). "Drug interactions in the treatment of Parkinson's disease". Journal of Neurology. 249 (Suppl 3): III/24–9. doi:10.1007/s00415-002-1305-0. PMID 12522568. S2CID 39469174.
  22. ^ DeVane, C. Lindsay (April 1983). "Pharmacokinetics (2nd edn, revised and expanded), M. Gibaldi and D. Perrier (Vol. 15 of Drugs and the pharmaceutical sciences), Marcel Dekker, New York, 1982". Biopharmaceutics & Drug Disposition. 4 (2): 201. doi:10.1002/bdd.2510040213. ISSN 0142-2782.
  23. ^ Blin O (December 2003). "The pharmacokinetics of pergolide in Parkinson's disease". Current Opinion in Neurology. 16 (Suppl 1): S9-12. doi:10.1097/00019052-200312001-00003. PMID 15180132. S2CID 1734931.
  24. ^ Kaye CM, Nicholls B (October 2000). "Clinical pharmacokinetics of ropinirole". Clinical Pharmacokinetics. 39 (4): 243–54. doi:10.2165/00003088-200039040-00001. PMID 11069211. S2CID 9977681.
  25. ^ Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M (April 2015). "An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome". Drugs. 75 (5): 487–501. doi:10.1007/s40265-015-0377-y. PMC 4382528. PMID 25795100.
  26. ^ Peterson SM, Urs N, Caron MG (2012-01-01), Robertson D, Biaggioni I, Burnstock G, Low PA (eds.), "Chapter 13 - Dopamine Receptors", Primer on the Autonomic Nervous System (Third Edition), Academic Press, pp. 67–70, doi:10.1016/B978-0-12-386525-0.00013-5, ISBN 9780123865250
  27. ^ "Dopamine D1-Like Receptor Family Signaling Pathways". www.rndsystems.com. Retrieved 2019-10-08.
  28. ^ Weng JJ, Wang LH, Zhu H, Xu WR, Wei YM, Wang ZY, et al. (2019). "3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study". Neuropsychiatric Disease and Treatment. 15: 2195–2203. doi:10.2147/NDT.S205933. PMC 6689661. PMID 31496702.
  29. ^ Ravikumar K, Sridhar B (May 2006). "Ropinirole hydrochloride, a dopamine agonist". Acta Crystallographica Section C. 62 (Pt 5): o265-7. Bibcode:2006AcCrC..62O.265R. doi:10.1107/S0108270106010535. PMID 16679599.
  30. ^ Banks WA (June 2009). "Characteristics of compounds that cross the blood-brain barrier". BMC Neurology. 9 (Suppl 1): S3. doi:10.1186/1471-2377-9-S1-S3. PMC 2697631. PMID 19534732.
  31. ^ Best JA, Nijhout HF, Reed MC (September 2009). "Homeostatic mechanisms in dopamine synthesis and release: a mathematical model". Theoretical Biology & Medical Modelling. 6 (1): 21. doi:10.1186/1742-4682-6-21. PMC 2755466. PMID 19740446.
  32. ^ Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, et al. (October 2000). "The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier". Brain Research. 879 (1–2): 115–21. doi:10.1016/s0006-8993(00)02758-x. PMID 11011012. S2CID 33605179.
  33. ^ a b Cannon JG (1983). "Structure-activity relationships of dopamine agonists". Annual Review of Pharmacology and Toxicology. 23: 103–29. doi:10.1146/annurev.pa.23.040183.000535. PMID 6347047.
  34. ^ Oda T, Kume T, Izumi Y, Takada-Takatori Y, Niidome T, Akaike A (November 2008). "Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells". European Journal of Pharmacology. 598 (1–3): 27–31. doi:10.1016/j.ejphar.2008.09.015. PMID 18835264.
  35. ^ Markstein R, Seiler MP, Jaton A, Briner U (March 1992). "Structure activity relationship and therapeutic uses of dopaminergic ergots". Neurochemistry International. Satellite Meeting of the XIth International Congress of Pharmacology. 20 (Suppl): 211S – 214S. doi:10.1016/0197-0186(92)90241-I. PMID 1365428. S2CID 27230073.
  36. ^ Perachon S, Schwartz JC, Sokoloff P (February 1999). "Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors". European Journal of Pharmacology. 366 (2–3): 293–300. doi:10.1016/S0014-2999(98)00896-6. PMID 10082211.
  37. ^ Platania CB, Salomone S, Leggio GM, Drago F, Bucolo C (2012-09-06). "Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation". PLOS ONE. 7 (9): e44316. Bibcode:2012PLoSO...744316P. doi:10.1371/journal.pone.0044316. PMC 3435408. PMID 22970199.
  38. ^ Borkar N, Mu H, Holm R (2018-11-01). "Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease". Asian Journal of Pharmaceutical Sciences. Formulation strategies and manufacturing technologies to enhance non-invasive drug delivery. 13 (6): 507–517. doi:10.1016/j.ajps.2017.11.004. ISSN 1818-0876. PMC 7032113. PMID 32104425.
  39. ^ Subramony JA (2006). "Apomorphine in dopaminergic therapy". Molecular Pharmaceutics. 3 (4): 380–5. doi:10.1021/mp060012c. PMID 16889431.
  40. ^ Risgaard R, Jensen M, Jørgensen M, Bang-Andersen B, Christoffersen CT, Jensen KG, et al. (January 2014). "Synthesis and SAR study of a novel series of dopamine receptor agonists". Bioorganic & Medicinal Chemistry. 22 (1): 381–92. doi:10.1016/j.bmc.2013.11.012. PMID 24296012.
  41. ^ Seeman P, Guan HC, Hirbec H (2009). "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse. 63 (8): 698–704. doi:10.1002/syn.20647. PMID 19391150. S2CID 17758902.
  42. ^ Conroy JL, Free RB, Sibley DR (April 2015). "Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor". ACS Chemical Neuroscience. 6 (4): 681–92. doi:10.1021/acschemneuro.5b00020. PMC 5234767. PMID 25660762.
  43. ^ FDA Announces Voluntary Withdrawal of Pergolide Products
  44. ^ Matera C, Quadri M, Pelucchi S, De Amici M, Dallanoce C (April 17, 2014). "A convenient synthesis of 4-(2-hydroxyethyl)indolin-2-one, a useful intermediate for the preparation of both dopamine receptor agonists and protein kinase inhibitors". Monatshefte für Chemie. 145 (7): 1139–1144. doi:10.1007/s00706-014-1211-z. hdl:2434/236639. S2CID 84265684.
  45. ^ Ng SS, Pang CC (March 2000). "In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist". British Journal of Pharmacology. 129 (5): 853–8. doi:10.1038/sj.bjp.0703119. PMC 1571905. PMID 10696081.
  46. ^ Watanabe, H.; Uramoto, H. (June 1986). "Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors". Neuropharmacology. 25 (6): 577–581. doi:10.1016/0028-3908(86)90208-X. PMID 3748312.
  47. ^ Zhang J, Tan LC (2016-04-08). "Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist". Current Neuropharmacology. 14 (4): 356–63. doi:10.2174/1570159X14666151208114634. PMC 4876591. PMID 26644151.
  48. ^ Tolosa E, Martí MJ, Valldeoriola F, Molinuevo JL (June 1998). "History of levodopa and dopamine agonists in Parkinson's disease treatment". Neurology. 50 (6 Suppl 6): S2–10, discussion S44–8. doi:10.1212/wnl.50.6_suppl_6.s2. PMID 9633679. S2CID 25603106.
  49. ^ Golan DE, Armstrong EJ, Armstrong AW (2017). Principles of pharmacology - the pathophysiologic basis of drug therapy. Philadelphia: Wolters Kluwer. pp. 214–215. ISBN 9781451191004.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dopamine_agonist&oldid=1258845848"